Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00479427 | A Study Of The Effects Of CB2 Compound Of GW842166 In Patients With Osteoarthritis | PHASE2 | COMPLETED | 1 | — | — | Jul 6, 2007 | Oct 9, 2007 | Jul 11, 2017 | 1 | United Kingdom |
The index consisted of 24 questions (5 for pain, 2 for stiffness and 17 for physical and composite functions). The visual analog scale (VAS; 0-100 millimeter \[mm\]) was utilized in this study and participants were asked to rate joint pain they had in last 24 hours in the 5 pain items. Participants were asked to rate pain while performing following activities: walking on a flat surface, going up or down stairs; at night while in bed; sitting or lying and standing upright. Higher score (100) indicates extreme pain and lower score (0) indicates no pain. It was assessed on Day 1 pre-dose (Baseline), Day 1 (1 hour post-dose) and Day 14 (2-4 hours post-dose). Change from Baseline was planned to be calculated by subtracting Baseline value from post-Baseline value. Due to the early termination of this study, no formal statistical analysis was performed. Only summarized data is available.
| Arm | Type | Description |
|---|---|---|
| Overall study | EXPERIMENTAL | overall study population |
| Name | Type | Description |
|---|---|---|
| GW842166 | DRUG | 100 mg once daily |
| Placebo | DRUG | once daily |
Inclusion Criteria: * Male or female patients, 50 to 80 years of age. * A female is eligible to participate in this study if she is of: a) non-childbearing potential (i.e., physiologically incapable of becoming pregnant, including any female who is post-menopausal (more than 1 year since last menst...